NeurONES Sees Significant Revenue and Net Profit Growth in 2024.
Key Highlights of NeurONES’ 2024 Performance
Revenue Growth
Net Profit Growth
Drivers of Growth
Strong Client Relationships
Innovative Solutions
Challenges and Opportunities
Market Competition
Improved cash flow enables better financial management and informed investment decisions.
Cash Flow Improvements
The company has seen a significant improvement in its cash flow, thanks to a decrease in working capital needs and a return to normal levels of capital spending. Key factors contributing to the improvement: + Decrease in working capital needs (- β¬8.5m) + Return to normal levels of capital spending (β¬11.8m) + Investment in the previous year’s cloud platform (β¬17.9m)
Upcoming Financial Reports
The company will release its financial projections for the current year, along with its first-quarter revenue report, on May 7. Details of the reports: + Financial projections for the current year + First-quarter revenue report + Release date: May 7
Conclusion
The company’s improved cash flow is a positive sign for its financial health and future prospects. With its financial projections and first-quarter revenue report, the company will provide more clarity on its financial performance and make it easier for investors to make informed decisions. As the company continues to grow and expand its operations, it is likely to face new challenges and opportunities.
The Dividend Proposal: A Key Aspect of the Company’s Strategy
The dividend proposal is a crucial aspect of the company’s strategy, as it aims to provide a return to shareholders while also maintaining a strong balance sheet. The proposed dividend of β¬1.3 per share is a significant increase from the previous year’s dividend of β¬1.1 per share, demonstrating the company’s commitment to rewarding its shareholders.
Key Benefits of the Dividend Proposal
The Company’s Financial Performance
The company’s financial performance has been strong in recent years, with revenue growth of 10-15% per annum.
[email protected] Investor Relations: NEURONES Paul-CΓ©sar Bonnel Tel.: +33 (0)1 41 37 41 37 [email protected] Attachment